Page last updated: 2024-08-24

topotecan and pm 01183

topotecan has been researched along with pm 01183 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Alexandre, J; Berton-Rigaud, D; Bohan, P; Casado, A; Del Campo, JM; Fernández Teruel, C; Fernández, C; Galmarini, CM; Gonzalez-Martin, A; Guerra Alía, EM; Kahatt, C; Pérez de la Haza, A; Poveda, A; Provansal, M; Ray-Coquard, I; Rodriguez, I; Soto, A	1
Drapkin, BJ; Farago, AF; Galmarini, CM; Kahatt, C; Lopez-Vilarino de Ramos, JA; Núñez, R; Paz-Ares, L	1
Adeyemi, A; Boccuti, A; Caisip, C; Hanvesakul, R; Jansen, JP; Naveh, N; Park, JE; Rengarajan, B; Wilson, FR	1

Reviews

1 review(s) available for topotecan and pm 01183

Article	Year
Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer. Journal of comparative effectiveness research, 2023, Volume: 12, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Carbolines; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan	2023

Trials

2 trial(s) available for topotecan and pm 01183

Article	Year
Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Jun-01, Volume: 28, Issue:6 Topics: Aged; Antineoplastic Agents; Carbolines; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Ovarian Neoplasms; Platinum; Topotecan	2017
ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. Future oncology (London, England), 2019, Volume: 15, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carbolines; Cyclophosphamide; Doxorubicin; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Platinum; Progression-Free Survival; Small Cell Lung Carcinoma; Topotecan; Tumor Microenvironment; Vincristine	2019

Article

Year

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Jun-01, Volume: 28, Issue:6

Topics: Aged; Antineoplastic Agents; Carbolines; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Ovarian Neoplasms; Platinum; Topotecan

2017

ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.

Future oncology (London, England), 2019, Volume: 15, Issue:3

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carbolines; Cyclophosphamide; Doxorubicin; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Platinum; Progression-Free Survival; Small Cell Lung Carcinoma; Topotecan; Tumor Microenvironment; Vincristine

2019